| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
47,900,000 |
| Market
Cap: |
53.65(M) |
| Last
Volume: |
92,722 |
Avg
Vol: |
374,904 |
| 52
Week Range: |
$1.04 - $2.66 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P SMALLCAP 600 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Enzo Biochem is a diagnostics, clinical lab, and life sciences company. Co.'s operating segments include: Enzo Clinical Lab, which is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies; Enzo Life Sciences, which manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide; Enzo Therapeutics, which is a biopharmaceutical venture that has developed multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, various of which are derived from the work of Enzo Life Sciences.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
417,900 |
| Total Buy Value |
$0 |
$0 |
$0 |
$873,769 |
| Total People Bought |
0 |
0 |
0 |
5 |
| Total Buy Transactions |
0 |
0 |
0 |
14 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Weiner Barry W |
President and CFO |
• • – |
2008-09-23 |
4 |
OE |
$5.45 |
$331,115 |
D/D |
60,755 |
1,398,369 |
|
- |
|
| Rabbani Shahram K |
Treasurer, Secretary |
• • – |
2008-07-18 |
4 |
S |
$13.31 |
$1,100,005 |
D/D |
(82,645) |
1,828,494 |
|
- |
|
| Rabbani Elazar |
Chairman and CEO |
• • – |
2008-05-27 |
5 |
GD |
$0.00 |
$0 |
D/D |
5,000 |
2,185,745 |
|
- |
|
| Rabbani Shahram K |
Treasurer and Secretary |
• • – |
2008-02-24 |
5 |
GD |
$0.00 |
$0 |
D/D |
3,000 |
1,828,494 |
|
- |
|
| Kent Stephen B H |
Director |
– • – |
2008-02-05 |
4 |
S |
$10.16 |
$35,568 |
D/D |
(3,500) |
0 |
|
- |
|
| Goldberg David C |
VP, Business Development |
• – – |
2008-02-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,000 |
94,391 |
|
- |
|
| Thalenfeld Barbara E |
VP, Corporate Development |
• – – |
2008-02-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,000 |
55,550 |
|
- |
|
| Delucca John |
Director |
– • – |
2008-01-14 |
4 |
OE |
$10.68 |
$9,559 |
D/D |
895 |
18,589 |
|
- |
|
| Kelker Norman E |
Senior Vice President |
• – – |
2007-12-20 |
4 |
S |
$12.75 |
$173,442 |
D/D |
(13,600) |
104,583 |
|
- |
|
| Rabbani Shahram K |
Treasurer, Secretary |
• • – |
2007-12-20 |
4 |
S |
$13.03 |
$974,642 |
D/D |
(74,797) |
2,056,538 |
|
- |
|
| Rabbani Shahram K |
Treasurer, Secretary |
• • – |
2007-12-19 |
4 |
S |
$13.12 |
$782,077 |
D/D |
(59,600) |
2,131,335 |
|
- |
|
| Rabbani Elazar |
Chairman and CEO |
• • – |
2007-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
10,179 |
2,190,745 |
|
- |
|
| Rabbani Shahram K |
Treasurer, Secretary |
• • – |
2007-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
10,179 |
2,190,745 |
|
- |
|
| Weiner Barry W |
President and CFO |
• • – |
2007-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
10,179 |
1,398,369 |
|
- |
|
| Goldberg David C |
VP, Business Development |
• – – |
2007-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,118 |
94,391 |
|
- |
|
| Thalenfeld Barbara E |
VP, Corporate Development |
• – – |
2007-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,118 |
55,550 |
|
- |
|
| Crescenzo Andrew R. |
Senior Vice President, Finance |
• – – |
2007-12-07 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
2,000 |
|
- |
|
| Bass Herbert B |
Senior Vice President, Finance |
• – – |
2007-12-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
203,744 |
|
- |
|
| Balezentis Carl W |
President, Enzo Life Sciences |
• – – |
2007-12-07 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
2,500 |
|
- |
|
| Thalenfeld Barbara E |
VP, Corporate Development |
• – – |
2007-10-26 |
4 |
S |
$12.48 |
$129,492 |
D/D |
(10,376) |
60,813 |
|
- |
|
| Rabbani Shahram K |
Treasurer and Secretary |
• • – |
2007-10-18 |
4 |
S |
$13.03 |
$1,053,196 |
D/D |
(80,800) |
2,081,640 |
|
- |
|
| Rabbani Shahram K |
Treasurer and Secretary |
• • – |
2007-10-17 |
4 |
S |
$13.10 |
$357,750 |
D/D |
(27,300) |
2,162,440 |
|
- |
|
| Rabbani Elazar |
Chairman and CEO |
• • – |
2007-10-12 |
5 |
GD |
$0.00 |
$0 |
D/D |
12,000 |
2,185,745 |
|
- |
|
| Bass Herbert B |
VP, Finance |
• – – |
2007-08-20 |
4 |
OE |
$11.66 |
$18,590 |
D/D |
1,595 |
201,744 |
|
- |
|
| Goldberg David C |
VP, Business Development |
• – – |
2007-08-09 |
4 |
A |
$0.00 |
$0 |
D/D |
3,191 |
99,654 |
|
- |
|
264 Records found
|
|
Page 7 of 11 |
|
|
0.03 (2.75%) 
